Brief: Sellas Life Sciences Announces Update On Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, In Acute Myeloid Leukemia
14/11/2022 13:00
Nov 14 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES ANNOUNCES UPDATE ON PHASE 3 REGAL
CLINICAL
TRIAL EVALUATING LEAD ASSET, GALINPEPIMUT-S, IN ACUTE MYELOID
LEUKEMIA
* SELLAS LIFE SCIENCES GROUP INC - 3D MEDICINES TO
PARTICIPATE IN
REGAL CLINICAL TRIAL, WHICH WILL TRIGGER SIGNIFICANT MILESTONE
PAYMENTS TO SELLAS
* SELLAS LIFE SCIENCES GROUP INC - OVERALL SURVIVAL OBSERVED
IN
POOLED PATIENT DATA TO DATE LEADS TO CHANGES IN STATISTICAL
ANALYSIS PLAN
* SELLAS LIFE SCIENCES GROUP INC - INTERIM ANALYSIS NOW AT
60
EVENTS AND FINAL ANALYSIS NOW AT 80 EVENTS IN REGAL CLINICAL
TRIAL
Source text for Eikon: ID:nGNX3TmPK0
Further company coverage: SLS.O
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses